Rheumatology Medical News about Arthritis, Rheumatoid Infliximab

Your Unread Messages

See All

Tracy Hampton, PhD

Clinical Trial Watch

Whole-Brain Radiation Affects Learning and Memory in Brain Cancer Patients

Roberta Buell, MBA
RACs In Full Gear

Dorothy J. Schirf, MD

Technology Advances

Circulating Breast Cancer Cells Validated as Index of Metastases

Sara Hartley

Cancer Science

Using Embryonic Stem Cells to Test Breast Cancer Genes

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Treatment of early RA with infliximab is beneficial
American Pharmacists Association, 11/04/09

Schuna AA – The addition of infliximab (Remicade—Centocor) to methotrexate resulted in a superior clinical response compared with the addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (RA) who did not respond to 3 to 4 months of methotrexate monotherapy.

<< Previous
Incidence and predictors of osteonecrosis among cyclosporin- or...

Next >>
Nutrition and bone: it is more than calcium and vitamin D